Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deyan Y Yosifov

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Hemasphere|November 15, 2019
From Biology to Therapy: The CLL Success StoryDeyan Y Yosifov, Christine Wolf, Stephan Stilgenbauer, et al.
Annals of the New York Academy of Sciences|September 3, 2009
Erucylphospho-N,N,N-trimethylpropylammonium shows substantial cytotoxicity in multiple myeloma cellsDeyan Y Yosifov, Spiro M Konstantinov, Martin R Berger
Leukemia Research|March 17, 2012
Interleukin-6, osteopontin and Raf/MEK/ERK signaling modulate the sensitivity of human myeloma cells to alkylphosphocholinesDeyan Y Yosifov, Christina Reufsteck, Spiro M Konstantinov, et al.
Cancer Biology & Therapy|May 15, 2007
The expression level of the tumor suppressor retinoblastoma protein (Rb) influences the antileukemic efficacy of erucylphospho-N,N,N-trimethylpropylammonium (ErPC3)Deyan Y Yosifov, Ilina K Dineva, Maya M Zaharieva, et al.
Leukemia Research|November 15, 2013
Alkylphosphocholines and curcumin induce programmed cell death in cutaneous T-cell lymphoma cell linesDeyan Y Yosifov, Kaloyan A Kaloyanov, Margarita L Guenova, et al.
Hematology (Amsterdam, Netherlands)|June 6, 2012
A particular expression pattern of CD13 epitope 7H5 in chronic lymphocytic leukaemia--a possible new therapeutic targetMargarita L Guenova, Antoaneta Michova, Gueorgui N Balatzenko, et al.
Cancer Chemotherapy and Pharmacology|February 24, 2010
Erucylphospho-N,N,N-trimethylpropylammonium (erufosine) is a potential antimyeloma drug devoid of myelotoxicityDeyan Y Yosifov, Plamen T Todorov, Maya M Zaharieva, et al.
Haematologica|October 15, 2020
Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1Eugen Tausch, Philipp Beck, Richard F Schlenk, et al.
Hemasphere|June 17, 2026
IGLV3-21<sup>R110</sup> and ibrutinib treatment: Results from the double-blind, randomized, placebo-controlled GCLLSG CLL12 trial in early-stage CLLDeyan Y Yosifov, Sandra Robrecht, Adam Giza, et al.
Blood|April 29, 2024
T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemiaPhilipp M Roessner, Isabelle Seufert, Vicente Chapaprieta, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Hemasphere|November 15, 2019
From Biology to Therapy: The CLL Success StoryDeyan Y Yosifov, Christine Wolf, Stephan Stilgenbauer, et al.
Annals of the New York Academy of Sciences|September 3, 2009
Erucylphospho-N,N,N-trimethylpropylammonium shows substantial cytotoxicity in multiple myeloma cellsDeyan Y Yosifov, Spiro M Konstantinov, Martin R Berger
Leukemia Research|March 17, 2012
Interleukin-6, osteopontin and Raf/MEK/ERK signaling modulate the sensitivity of human myeloma cells to alkylphosphocholinesDeyan Y Yosifov, Christina Reufsteck, Spiro M Konstantinov, et al.
Cancer Biology & Therapy|May 15, 2007
The expression level of the tumor suppressor retinoblastoma protein (Rb) influences the antileukemic efficacy of erucylphospho-N,N,N-trimethylpropylammonium (ErPC3)Deyan Y Yosifov, Ilina K Dineva, Maya M Zaharieva, et al.
Leukemia Research|November 15, 2013
Alkylphosphocholines and curcumin induce programmed cell death in cutaneous T-cell lymphoma cell linesDeyan Y Yosifov, Kaloyan A Kaloyanov, Margarita L Guenova, et al.
Hematology (Amsterdam, Netherlands)|June 6, 2012
A particular expression pattern of CD13 epitope 7H5 in chronic lymphocytic leukaemia--a possible new therapeutic targetMargarita L Guenova, Antoaneta Michova, Gueorgui N Balatzenko, et al.
Cancer Chemotherapy and Pharmacology|February 24, 2010
Erucylphospho-N,N,N-trimethylpropylammonium (erufosine) is a potential antimyeloma drug devoid of myelotoxicityDeyan Y Yosifov, Plamen T Todorov, Maya M Zaharieva, et al.
Haematologica|October 15, 2020
Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1Eugen Tausch, Philipp Beck, Richard F Schlenk, et al.
Hemasphere|June 17, 2026
IGLV3-21<sup>R110</sup> and ibrutinib treatment: Results from the double-blind, randomized, placebo-controlled GCLLSG CLL12 trial in early-stage CLLDeyan Y Yosifov, Sandra Robrecht, Adam Giza, et al.
Blood|April 29, 2024
T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemiaPhilipp M Roessner, Isabelle Seufert, Vicente Chapaprieta, et al.
Pageof 1